Lv6
1664 积分 2021-08-03 加入
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials
23天前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
1个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
1个月前
已完结
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high
2个月前
已完结
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
2个月前
已关闭
Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer
2个月前
已完结
Therapy with oncolytic viruses: progress and challenges
2个月前
已完结
NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors
3个月前
已完结
Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA)
3个月前
已完结
FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro)
3个月前
已完结
皖公网安备34019202002308
